TODO: Skip to main content
Top
Gepubliceerd in:

16-05-2021

Mapping the Memorial Anxiety Scale for Prostate Cancer to the SF-6D

Auteurs: Daniel O. Erim, Antonia V. Bennett, Bradley N. Gaynes, Ram Sankar Basak, Deborah Usinger, Ronald C. Chen

Gepubliceerd in: Quality of Life Research | Uitgave 10/2021

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

To create a crosswalk that predicts Short Form 6D (SF-6D) utilities from Memorial Anxiety Scale for Prostate Cancer (MAX-PC) scores.

Methods

The data come from prostate cancer patients enrolled in the North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS, N = 1016). Cross-sectional data from 12- to 24-month follow-up were used as estimation and validation datasets, respectively. Participants’ SF-12 scores were used to generate SF-6D utilities in both datasets.
Beta regression mixture models were used to evaluate SF-6D utilities as a function of MAX-PC scores, race, education, marital status, income, employment status, having health insurance, year of cancer diagnosis and clinically significant prostate cancer-related anxiety (PCRA) status in the estimation dataset. Models’ predictive accuracies (using mean absolute error [MAE], root mean squared error [RMSE], Akaike information criterion [AIC] and Bayesian information criterion [BIC]) were examined in both datasets. The model with the highest prediction accuracy and the lowest prediction errors was selected as the crosswalk.

Results

The crosswalk had modest prediction accuracy (MAE = 0.092, RMSE = 0.114, AIC = − 2708 and BIC = − 2595.6), which are comparable to prediction accuracies of other SF-6D crosswalks in the literature. About 24% and 52% of predictions fell within ± 5% and ± 10% of observed SF-6D, respectively. The observed mean disutility associated with acquiring clinically significant PCRA is 0.168 (standard deviation = 0.179).

Conclusion

This study provides a crosswalk that converts MAX-PC scores to SF-6D utilities for economic evaluation of clinically significant PCRA treatment options for prostate cancer survivors.
Bijlagen
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.
Literatuur
Deze inhoud is alleen zichtbaar als je bent ingelogd en de juiste rechten hebt.
Metagegevens
Titel
Mapping the Memorial Anxiety Scale for Prostate Cancer to the SF-6D
Auteurs
Daniel O. Erim
Antonia V. Bennett
Bradley N. Gaynes
Ram Sankar Basak
Deborah Usinger
Ronald C. Chen
Publicatiedatum
16-05-2021
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 10/2021
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-021-02871-9